Page last updated at 12:08 GMT, Wednesday, 22 April 2009 13:08 UK

NHS to review sight drug decision

Allan Farley
Allan Farley could lose his sight if he is not treated with the Lucentis drug.

An NHS trust has pledged to review its decision to refuse a father-of-two treatment which consultants said could save his sight.

Allan Farley, 46, from Telford, suffers from a degenerative eye condition but had been denied the Lucentis drug by Telford and Wrekin Primary Care Trust.

A two-year course of injections can cost the NHS up to £18,000.

The trust said a treatment panel would look at the decision on 28 April following new evidence.

The injections have been available on the NHS as a treatment for other conditions since last April.

New evidence

A spokesman for the trust said: "At the time of Mr Farley's initial review, there was no evidence that the treatment being sought would be effective in treating his condition.

"Since these hearings, the Royal College of Ophthalmologists has brought to our attention new case study evidence.

"This evidence will be reviewed at the trust's individual and specialist treatments panel."

Mr Farley, who suffers from punctate inner choroidopathy, which can lead to blindness, has called for the drug to be made available to all patients and was due to present his case before Parliament.

He said: "We want a standard process for all the PCTs up and down the country, because we are aware that people have received funding for this who are of a similar age to me and with a similar condition."



Print Sponsor


SEE ALSO
Father in fight for sight drug
21 Apr 09 |  Shropshire
Father denied sight drug by trust
14 Mar 09 |  Shropshire
Lucentis: An NHS dilemma
27 Aug 08 |  Health

RELATED INTERNET LINKS
The BBC is not responsible for the content of external internet sites


FEATURES, VIEWS, ANALYSIS
Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit

BBC navigation

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.

Americas Africa Europe Middle East South Asia Asia Pacific